2003 Leads Pharmaceutical research 
PM360
NOVEMBER 12, 2024
One in three people is expected to develop a neurological condition in their lifetime, and neurological diseases are the leading cause of disability. Before Sage, he served as president of Alnylam Pharmaceuticals, Inc. since 2007, and he previously held the position of chief operating officer when he first joined the company in 2003.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Andrea Pfeifer, PhD In 2003, Andrea Pfeifer co-founded AC Immune SA.
Expert insights. Personalized for you.
52 
Let's personalize your content